Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29179156 | 1.00 | GRM4 (0.43) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL2996171 | 0.80 | GRM4 (0.43) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL7487653 | 0.75 | ENPP2 (0.41) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL7487665 | 0.75 | ENPP2 (0.41) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL7487673 | 0.75 | ENPP2 (0.41) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL7487657 | 0.75 | ENPP2 (0.41) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL20866285 | 0.71 | ENPP2 (0.47) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL12181289 | 0.71 | ENPP2 (0.47) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL19316021 | 0.69 | LMNA (0.52) | GRM4LMNATSHRMEN1CYP3A4 | |
| SCHEMBL4482850 | 0.68 | AKR1C3 (0.47) | GRM4LMNATSHRAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321269-B1 | PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | INTERVET INT BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| EP-1928820-B1 | A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL | INTERVET INT BV (NL) | 2014-01-29 | — | — | EP | disclosed |
| US-8314252-B2 | Process for preparing oxazoline-protected aminodiol compounds useful as intermediates to florfenicol | INTERVET INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110166359-A1 | PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | INTERVET INTERNATIONAL B.V. (NL) | 2011-07-07 | — | — | US | disclosed |
| EP-2321269-A2 | PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | Intervet International B.V. (NL) | 2011-05-18 | — | — | EP | disclosed |
| US-7786329-B2 | Process for preparing ester oxazolidine compounds and their conversion to Florfenicol | INTERVET INC. (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2010014566-A2 | PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | INTERVET INTERNATIONAL B.V. (NL) | 2010-02-04 | — | — | WO | disclosed |
| EP-1934189-A2 | A PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | Schering-Plough Ltd. (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934190-A2 | AN IMPROVED PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | Schering-Plough Ltd. (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1928820-A2 | A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL | Schering-Plough Ltd. (CH) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007030386-A2 | AN IMPROVED PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | SCHERING-PLOUGH LTD. (CH) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030385-A2 | A PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | SCHERING-PLOUGH LTD. (CH) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030405-A2 | A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL | SCHERING-PLOUGH LTD. (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20070055080-A1 | Process for preparing ester oxazolidine compounds and their conversion to Florfenicol | SCHERING-PLOUGH ANIMAL HEALTH CORP. | 2007-03-08 | — | — | US | disclosed |
| US-20070055067-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to Florfenicol | SCHERING-PLOUGH ANIMAL HEALTH CORP. | 2007-03-08 | — | — | US | disclosed |
| US-20070055066-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol | SCHERING-PLOUGH ANIMAL HEALTH CORP | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055080-A1 | Process for preparing ester oxazolidine compounds and their conversion to Florfenicol | CYP4F8, CYP4F2, CYP2F1 | GRM4 2145/4885LMNA 1934/4885TSHR 3720/4885 |
| US-20070055067-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to Florfenicol | DHFR, DPYD, AMPD2 | GRM4 3339/4885LMNA 1668/4885TSHR 4433/4885 |
| US-20070055066-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol | DHFR, DPYD, AMPD2 | GRM4 3339/4885LMNA 1668/4885TSHR 4433/4885 |
| US-20110166359-A1 | PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | PFAS, DHFR, OXA1L | GRM4 2062/4885LMNA 1876/4885TSHR 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.